Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial (Q43624795)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial |
scientific article |
Statements
1 reference
Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial (English)
1 reference
J Hensen
1 reference
C P Howard
1 reference
V Walter
1 reference
T Thuren
1 reference
25 September 2013
1 reference
1 reference
39
1 reference
6
1 reference
524-531
1 reference
Identifiers
1 reference
1 reference